Acute Myeloid Leukaemia
Phase II study of the tolerability of adjunctive azacitidine in patients undergoing reduced intensity allogeneic stem cell transplantation for acute myeloid leukaemia and myelodysplasia.
Phase II study of the tolerability of adjunctive azacitidine in patients undergoing reduced intensity allogeneic stem cell transplantation for acute myeloid leukaemia and myelodysplasia.
The AML 17 trial has two distinct parts:
i.For patients with acute myeloid leukaemia (AML), (other than acute promyelocytic leukaemia) and High Risk Myelodysplasia, as defined by the WHO Classification (2001) (Appendix A, protocol).
ii.For adults with acute promyelocytic leukaemia (APL).
A pilot safety / tolerability study of Lenalidomide administered as monotherapy and in combination with standard chemotherapy for
Acute Myeloid Leukaemia / high-risk Myelodysplastic Syndrome with structural abnormalities of chromosome 5
Novartis Panobinostat Refractory AML
A Phase II Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous Leukemia (AML)
The AML16 Trial will evaluate several relevant therapeutic questions in Acute Myeloid Leukaemia (AML), as defined by the WHO, and High Risk Myelodysplastic Syndrome. The trial is primarily designed for patients over 60 years, but younger patients who may not be considered suitable for the concurrent MRC AML Trial for
younger patients may also enter.
A phase 2 open label, AC220 monotherapy efficacy study in patients with acute myeloid leukaemia (AML) with FLT3-ITD activating mutations.
A multi-center, open-label, Phase I study of single agent RO5045337 administered orally in patients with acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML) in blast phase, or refractory chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL / SCLL).
This study will determine the maximum tolerated dose of RO5045337 and the optimal associated 4 weekly dosing schedule of RO5045337, administered as monotherapy in patients with hematologic neoplasms.
A first cohort of patients will receive the starting dose of 20mg/m2/day po, once daily for 10 days in each 28 day cycle. Subsequent cohorts of patients will receive dose escalations, and possible changes in dosing schedule, based on tolerability and pharmacokinetic knowledge gained from prior treatment cohorts.
The anticipated time on study treatment is until disease progression or intolerable toxicity.